02/09/2026
Today is an exciting day for our Company as we announce the official closing of Waters’ combination with the BD Biosciences & Diagnostic Solutions businesses. Together we are creating a global life sciences and diagnostics leader, equipped with category-defining technologies, complementary scientific expertise, and a shared commitment to improving global health. We are poised to advance the release of high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance.
We are also pleased to welcome Claire Fraser, Ph.D., to our Board of Directors. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology.
Alongside this important milestone, we released our full year 2025 financial results, including high single-digit revenue growth and double-digit adjusted EPS growth. The team’s operational excellence and innovation fueled another year of strong ex*****on and new product launches aimed at addressing our customers’ greatest needs.
As we begin this new chapter, we are excited to welcome our new colleagues to Waters and look forward to working together as we turn scientific challenges into breakthroughs that improve lives worldwide.
Click to learn more: www.waters.com/combination